Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Receivables (2016 - 2025)

Historic Receivables for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Altimmune's Receivables rose 11222.53% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 11222.53%. This contributed to the annual value of $944000.0 for FY2024, which is 2204.79% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Receivables is $1.5 million, which was up 11222.53% from $321000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Receivables ranged from a high of $4.8 million in Q1 2021 and a low of $136000.0 during Q2 2023
  • Over the past 5 years, Altimmune's median Receivables value was $724000.0 (recorded in 2024), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Altimmune's Receivables crashed by 9598.04% in 2022, and later soared by 60000.0% in 2023.
  • Altimmune's Receivables (Quarter) stood at $429000.0 in 2021, then plummeted by 59.67% to $173000.0 in 2022, then surged by 600.0% to $1.2 million in 2023, then dropped by 22.05% to $944000.0 in 2024, then surged by 63.67% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $321000.0 for Q2 2025, and $907000.0 during Q1 2025.